Kagocel in the therapy of influenza and acute respiratory viral infections: Data analysis and systematization from the results of preclinical and clin

[tetano]

Ter Arkh. 2017;89(8):113-119. doi: 10.17116/terarkh2017898113-119.
[h=1][Kagocel in the therapy of influenza and acute respiratory viral infections: Data analysis and systematization from the results of preclinical and clinical trials].[/h] [Article in Russian; Abstract available in Russian from the publisher]
Sologub TV[SUP]1[/SUP], Tsvetkov VV[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] in English, Russian
The article provides the summarized data of clinical trials evaluating the efficacy and safety of kagocel used to prevent and treat influenza and acute respiratory viral infections of different etiologies. The results of numerous preclinical and clinical trials suggest that the kagocel substance is highly safe and that it is appropriate to use the drug for the treatment and prevention of influenza and acute respiratory viral infections of another etiology.


[h=4]KEYWORDS:[/h] acute respiratory viral infection; immunomodulatory therapy; influenza; interferon; interferon inducer

PMID: 28914861 DOI: 10.17116/terarkh2017898113-119